Search

Thiamine disulfide

Lunacalcipol

CTA018 will be the first drug with this novel dual mechanism of action to enter clinical development. … secretion which may be involved in the etiology of psoriasis.

Odanacatib

The drug made it to phase III trials before abandoned due to increased stroke. … Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

Nonoxynol-9

It is the most commonly used spermicidal contraceptive in the UK and the USA. In several European countries, spermicides are no longer on the market. … N-9 has been in use for more than 30 years as an over-the-counter (OTC) drug in creams, gels, foams and condom lubricants.

XTL-6865

It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.

Posizolid

In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though

Methallenestril

Methylestrenolone

Oral Polio Vaccine

Strains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that occurs after infection with … The vaccine is created by weakening the wildtype before being placed into the oral vaccine.

Nedaplatin

Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.